Biological functions and role of mitogen-activated protein kinase activated protein kinase 2 (MK2) in inflammatory diseases

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pharmacological Reports

• Publication date

  2017-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.pharep.2017.03.023PMID 28582691
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials.

  2016influential reference
• Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres.

  2014cited by this paper
• Mitogen-Activated Protein Kinase–Activated Protein Kinase 2 in Neuroinflammation, Heat Shock Protein 27 Phosphorylation, and Cell Cycle: Role and Targeting

  2014cited by this paper
• What goes up must come down: molecular basis of MAPKAP kinase 2/3-dependent regulation of the inflammatory response and its inhibition

  2013cited by this paper
• The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinases (MAPKAPKs) in Inflammation

  2013cited by this paper
• Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis

  2013cited by this paper
• SnapShot: p38 MAPK substrates.

  2013influential reference
• The p38 MAPK Pathway in Rheumatoid Arthritis: A Sideways Look

  2012cited by this paper
• Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells.

  2012influential reference
• A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors.

  2012cited by this paper
• Binding Affinity Prediction for Ligands and Receptors Forming Tautomers and Ionization Species: Inhibition of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2)

  2012influential reference
• Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases

  2012influential reference
• Discovery of a Potent Dihydrooxadiazole Series of Non-ATP-Competitive MK2 (MAPKAPK2) Inhibitors.

  2012cited by this paper
• Distinct Functions of the Mitogen-activated Protein Kinase-activated Protein (MAPKAP) Kinases MK2 and MK3

  2011influential reference
• How were new medicines discovered?

  2011cited by this paper
• Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series.

  2011cited by this paper
• Faculty Opinions recommendation of Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ).

  2011cited by this paper
• Structure-based lead identification of ATP-competitive MK2 inhibitors.

  2011cited by this paper
• Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases

  2011cited by this paper
• Microglial p38a MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Ab)

  2011cited by this paper
• The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-alpha pathway of systemic and cutaneous inflammation.

  2010cited by this paper
• DBM1285 Suppresses Tumor Necrosis Factor α Production by Blocking p38 Mitogen-Activated Protein Kinase/Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Signaling Pathway

  2010influential reference
• Phosphorylation of Tristetraprolin by MK2 Impairs AU-Rich Element mRNA Decay by Preventing Deadenylase Recruitment

  2010cited by this paper
• A Benzothiophene Inhibitor of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Inhibits Tumor Necrosis Factor α Production and Has Oral Anti-Inflammatory Efficacy in Acute and Chronic Models of Inflammation

  2010influential reference
• TRIF Signaling Stimulates Translation of TNF-α mRNA via Prolonged Activation of MK2

  2010cited by this paper
• MK2 signaling: lessons on tissue specificity in modulation of inflammation.

  2010cited by this paper
• MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin.

  2010influential reference
• Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency.

  2009cited by this paper
• Mitogen activated protein kinases: a role in inflammatory bowel disease?

  2009cited by this paper
• Low-molecular-weight MK2 inhibitors: a tough nut to crack!

  2009cited by this paper
• Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study

  2009cited by this paper
• Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice.

  2009cited by this paper
• Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency.

  2009cited by this paper
• Mitogen-activated protein kinase-activated protein kinase 2 (MK2) modulates key biological pathways associated with OA disease pathology.

  2009cited by this paper
• Targeting innate immunity protein kinase signalling in inflammation

  2009cited by this paper
• “Go upstream, young man”: lessons learned from the p38 saga

  2009cited by this paper
• MK2: a novel molecular target for anti-inflammatory therapy.

  2008influential reference
• Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism.

  2008cited by this paper
• MAP‐kinase‐activated protein kinase 2 expression and activity is induced after neuronal depolarization

  2008cited by this paper
• Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases

  2008cited by this paper
• MK2 and MK3--a pair of isoenzymes?

  2008cited by this paper
• The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling

  2008influential reference
• Novel tetrahydro-beta-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).

  2007cited by this paper
• Crystal Structure of the P38α-MAPKAP Kinase 2 Heterodimer*

  2007cited by this paper
• Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).

  2007cited by this paper
• Protein kinases as small molecule inhibitor targets in inflammation.

  2007cited by this paper
• MK2 controls the level of negative feedback in the NF-κB pathway and is essential for vascular permeability and airway inflammation

  2007cited by this paper
• Novel strategies for inhibition of the p38 MAPK pathway.

  2007cited by this paper
• Molecular basis of MAPK-activated protein kinase 2:p38 assembly

  2007cited by this paper
• Distinct role of MAPKAPK-2 in the regulation of TNF gene expression by Toll-like receptor 7 and 9 ligands.

  2007cited by this paper
• Structural basis for a high affinity inhibitor bound to protein kinase MK2.

  2007cited by this paper
• MAPKAP Kinase 2-Deficient Mice Are Resistant to Collagen-Induced Arthritis

  2006cited by this paper
• The Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinases MK2 and MK3 Cooperate in Stimulation of Tumor Necrosis Factor Biosynthesis and Stabilization of p38 MAPK

  2006cited by this paper
• Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Regulates Tumor Necrosis Factor mRNA Stability and Translation Mainly by Altering Tristetraprolin Expression, Stability, and Binding to Adenine/Uridine-Rich Element

  2006cited by this paper
• MAPKAP kinases — MKs — two's company, three's a crowd

  2006cited by this paper
• MAPK-activated Protein Kinase 2 Deficiency in Microglia Inhibits Pro-inflammatory Mediator Release and Resultant Neurotoxicity

  2006cited by this paper
• Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 21

  2006cited by this paper
• MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein.

  2005cited by this paper
• Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).

  2005cited by this paper
• p38 MAP kinase inhibitors: many are made, but few are chosen.

  2005influential reference
• Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases.

  2005cited by this paper
• Activating p38 MAPK: New Tricks for an Old Kinase

  2005cited by this paper
• MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein

  2005influential reference
• Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development.

  2005cited by this paper
• MK2‐induced tristetraprolin:14‐3‐3 complexes prevent stress granule association and ARE‐mRNA decay

  2004cited by this paper
• Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.

  2004cited by this paper
• Biochemical mechanisms of drug action: what does it take for success?

  2004cited by this paper
• Biological agents in rheumatoid arthritis.

  2004cited by this paper
• The p38 MAP kinase pathway as a therapeutic target in inflammatory disease.

  2004cited by this paper
• Catalytically active MAP KAP kinase 2 structures in complex with staurosporine and ADP reveal differences with the autoinhibited enzyme.

  2003influential reference
• p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

  2003influential reference
• Feedback control of the protein kinase TAK1 by SAPK2a/p38α

  2003cited by this paper
• Mitogen-Activated Protein Kinase-Activated Protein Kinase 2-Deficient Mice Show Increased Susceptibility to Listeria monocytogenes Infection

  2002cited by this paper
• Distinct Cellular Functions of MK2

  2002cited by this paper
• Structure of Mitogen-activated Protein Kinase-activated Protein (MAPKAP) Kinase 2 Suggests a Bifunctional Switch That Couples Kinase Activation with Nuclear Export*

  2002cited by this paper
• Is MK2 (mitogen-activated protein kinase-activated protein kinase 2) the key for understanding post-transcriptional regulation of gene expression?

  2001cited by this paper
• FRET‐based detection of different conformations of MK2

  2001influential reference
• Inhibition of p38 MAP kinase as a therapeutic strategy.

  2000cited by this paper
• Deficiency of the Stress Kinase P38α Results in Embryonic Lethality

  2000cited by this paper
• Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis.

  2000cited by this paper
• Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells.

  2000cited by this paper
• p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials.

  1999cited by this paper
• Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2.

  1998cited by this paper
• Characterization of an Autoinhibitory Domain in Human Mitogen-activated Protein Kinase-activated Protein Kinase 2 (*)

  1995cited by this paper
• Identification of novel phosphorylation sites required for activation of MAPKAP kinase‐2.

  1995cited by this paper
• Autoimmunity to type II collagen an experimental model of arthritis

  1977cited by this paper

• Evaluation of Pyrrolone‐Fused Benzosuberene MK2 Inhibitors as Promising Therapeutic Agents for HNSCC: In Vitro Efficacy, In‐Vivo Safety, and Pharmacokinetic Profiling

  2025cites this paper
• Triptolide-mediated immunomodulation of macrophages: from pathophysiology to therapy

  2025cites this paper
• Role of Atypical MAPK p38 Signaling in the Progression of Influenza A‐Induced Acute Lung Injury

  2025cites this paper
• MK2 deficiency decreases mortality in male mice during the inflammatory phase after myocardial infarction

  2025cites this paper
• MK2 Inhibition as a Novel Treatment for Fibrosis in Primary Sclerosing Cholangitis via an IL-22-Dependent Mechanism

  2025cites this paper
• Therapeutic potential of MK2 kinase inhibition in pathogenesis of Parkinson’s disease

  2025influential citation
• MAPK-activated protein kinase 2 is associated with poor prognosis of glioma patients and immune inhibition in glioma

  2024cites this paper
• Loss of MK2 Enhances Radiation-Mediated Apoptosis in Bladder Cancer

  2024cites this paper
• Remodeling tumor‐associated macrophage for anti‐cancer effects by rational design of irreversible inhibition of mitogen‐activated protein kinase‐activated protein kinase 2

  2024cites this paper
• Unraveling the interplay between vital organelle stress and oxidative stress in idiopathic pulmonary fibrosis.

  2024cites this paper
• MK2 deficiency decreases mortality during the inflammatory phase after myocardial infarction in mice

  2023cites this paper
• Function and inhibition of P38 MAP kinase signaling: Targeting multiple inflammation diseases.

  2023cites this paper
• Comparative in silico, in vitro and ex vivo anti‐inflammatory activity of quercetin

  2023cites this paper
• Dietary Curcumin Attenuates Hepatic Cellular Senescence by Suppressing the MAPK/NF-κB Signaling Pathway in Aged Mice

  2023cites this paper
• Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis

  2023cites this paper
• Excessive hydrogen sulfide causes lung and brain tissue damage by promoting PARP1/Bax and C9 and inhibiting LAMB1

  2022cites this paper
• Novel therapies in axial spondyloarthritis.

  2022cites this paper
• The MK2 cascade mediates transient alteration in mGluR‐LTD and spatial learning in a murine model of Alzheimer's disease

  2022cites this paper
• Inhibition of Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinase 2 (MK2) is Protective in Pulmonary Hypertension

  2021cites this paper
• MicroRNA-24-3p Inhibits Microglia Inflammation by Regulating MK2 Following Spinal Cord Injury

  2021cites this paper
• Inhibition of MK2 kinase as a potential therapeutic target to control neuroinflammation in Alzheimer’s disease

  2021influential citation
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study

  2021cites this paper
• Mitogen‐activated protein kinase‐activated protein kinase‐2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancer

  2021cites this paper
• Involvement of mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2) in endothelial dysfunction associated with pulmonary hypertension.

  2021cites this paper
• Monomeric C-reactive protein affects cell injury and apoptosis through activation of p38 mitogen-activated protein kinase in human coronary artery endothelial cells

  2020cites this paper
• Dengue virus non-structural protein 1 activates the p38 MAPK pathway to decrease barrier integrity in primary human endothelial cells.

  2020cites this paper
• Current Insights of Inhibitors of p38 Mitogen-Activated Protein Kinase in Inflammation.

  2020cites this paper
• Tumor suppressor death-associated protein kinase 1 inhibits necroptosis by p38 MAPK activation

  2020cites this paper
• Kinase inhibitors in the treatment of obstructive pulmonary diseases.

  2020cites this paper
• MicroRNA expression profile of Lacrimal Glands in rabbit autoimmune dacryoadenitis model

  2020cites this paper
• The effect of interleukin-22 on osteogenic differentiation and the osteoclastogenic response of Human periodontal ligament fibroblasts in vitro.

  2020cites this paper
• Novel Therapeutic Potential of Mitogen-Activated Protein Kinase Activated Protein Kinase 2 (MK2) in Chronic Airway Inflammatory Disorders.

  2019cites this paper
• Protective effects of VGX‐1027 in PM2.5‐induced airway inflammation and bronchial hyperresponsiveness

  2019cites this paper
• Intranasal MMI-0100 Attenuates Aβ1−42- and LPS-Induced Neuroinflammation and Memory Impairments via the MK2 Signaling Pathway

  2019influential citation
• Substrate-based kinase activity inference identifies MK2 as driver of colitis.

  2019cites this paper
• MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma

  2019cites this paper
• p38MAPK plays a pivotal role in the development of acute respiratory distress syndrome

  2019cites this paper
• MiR‐137 inhibited inflammatory response and apoptosis after spinal cord injury via targeting of MK2

  2018cites this paper
• MK2 mediates macrophage activation and acute lung injury by regulating let-7e miRNA.

  2018cites this paper
• Modulating ADME Properties by Fluorination: MK2 Inhibitors with Improved Oral Exposure.

  2018cites this paper
• Status of Neuropharmacology Research in India

  2018cites this paper
• Pterostilbene Attenuates Hexavalent Chromium-Induced Allergic Contact Dermatitis by Preventing Cell Apoptosis and Inhibiting IL-1β-Related NLRP3 Inflammasome Activation

  2018cites this paper
• 4‐O‐carboxymethylascochlorin protected against microglial‐mediated neurotoxicity in SH‐SY5Y and BV2 cocultured cells from LPS–induced neuroinflammation and death by inhibiting MAPK, NF‐κB, and Akt pathways

  2018cites this paper
• Differential regulation of cytokine and chemokine expression by MK2 and MK3 in airway smooth muscle cells.

  2018cites this paper
• Downregulation of iNOS, IL-1β, and P2X7 Expression in Mast Cells via Activation of PAR4 Contributes to the Inhibition of Visceral Hyperalgesia in Rats

  2018cites this paper
• Patent Highlights June-July 2017.

  2017cites this paper